TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01836484

Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion-weighted MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorodeoxyglucose-18-PET/CT

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluoro-ethyl-coline-PET/CT
Study: NCT01481116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
Study: NCT03997552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-incised papillae surgical approach (NIPSA)
Description: Periodontal reconstructive surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: marginal approach by palatal incision
Description: Periodontal reconstructive surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surgical technique (MIST)
Description: Periodontal reconstructive surgery
Study: NCT03985020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stevia Intervention
Description: We will use commercially available stevia sweetened soft drink Zevia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water Intervention
Description: Bottled Water
Study: NCT05174026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo 18F-FDG PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FDG PET-MRI
Study: NCT02303509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB5857 Part 1
Description: Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 1 mg, 5 mg, 10 mg or 15 mg~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB5857 Part 2
Description: Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 5 mg, 8 mg, 15 mg~Route of administration: Oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active substance: Placebo~Pharmaceutical form: Capsule~Concentration: Avicel PH 102, 50 mg~Route of administration: Oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active substance: Placebo~Pharmaceutical form: Capsule~Concentration: Avicel PH 102, 50 mg~Route of administration: Oral
Study: NCT03030027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connecting Through Caregiving
Description: The Connecting Through Caregiving intervention focuses on reappraisal exercises on intergeneration relationships in caregiving, involving the following: 1) enhancing self-awareness of the caregiver, 2) developing interpersonal empathy for the care-recipient, 3) help-seeking in caregiving, 4) balancing self-care and caring and 5) negotiating action plans.

Intervention type: OTHER
Group type: OTHER
Intervention: Basic Skills Building
Description: Skill building involves: 1) monitoring activities, 2) pleasant event scheduling, 3) communicating with the care recipient, 4) communicating with family members and 5) review implementation
Study: NCT03148548

Intervention type: GENETIC
Intervention: thrombophilia screening
Description: genetic Evaluation of Factor-V-Leiden, Factor-II_G20210A Mutation;

Intervention type: GENETIC
Intervention: thrombophilia screening
Description: genetic Evaluation of Factor-V-Leiden, Factor-II_G20210A Mutation;
Study: NCT04026906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue
Description: One drop of cyanoacrylate glue will be applied to the intravenous (IV) insertion site and another drop under the hub of the IV catheter

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transparent polyurethane dressing
Description: The IV will be secured in the usual manner with tape and a transparent dressing.
Study: NCT02473068

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Study: NCT03825289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT00772096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Study: NCT03779412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Happiness Trap
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A Mindfulness-Based Stress Reduction Workbook
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
Study: NCT03857802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene intervention
Description: An individual education will be carried out following a bidirectional feedback method. It is intended to develop skills to make conscious and autonomous decisions. The explanation will consist:~1. Information and reading with discussion of the educational sheet: The 9 tips for a healthy sleep will be read, point by point. The nurse will be open to discuss those that generate doubt.~2. Confrontation: even if the patient does not ask any questions about it, it will be necessary to ask if he has understood the advice.~3. Participated information: Questions will be asked to the patient such as: Did you already know any of these tips?.~A telephone call per month will be made as an educational reinforcement to the intervention.
Study: NCT02733978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the ozone generator device (Human Pro medic, German)
Description: noninvasive oxygen-ozone treatments with 52 ug/mL ozone (total volume: 20-50 mL) in a special bag for 30 min per day for 20 days using the ozone generator device (Human Pro Medic, German)
Study: NCT01099085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: simvastatin 40 mg qd daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05372016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
Description: 9vHPV vaccine ,0.5mL, three doses, 0,2,6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: GARDASIL ®9
Description: GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
Study: NCT04162951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ordinary approach paravertebral block
Description: Ultrasound guided thoracic paravertebral block. At the appropriate dermatome, the needle (22-gauge, 8-10-cm, short bevelled spinal needle, or a Touhy needle if a catheter is to be placed) is inserted 2.5-3 cm lateral to the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process at a variable depth (2-4 cm) depending on the build of the individual. The needle is then walked above the transverse process and gradually advanced until a loss of resistance to air or saline, or a subtle 'click' is felt as the superior costotransverse ligament is penetrated, usually within 1-1.5 cm from the superior edge of the transverse process.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrolaminar paravertebral block
Description: In the retrolaminar approach to TPVB or retrolaminar block (RB), local anesthetic (LA) is injected into the retrolaminar plane to achieve a truncal sensory block like that of traditional TPVB. It has been postulated that during RB, LA spreads from the injection plane to the thoracic paravertebral space (TPVS) through the superior costotransverse ligament (SCTL). Retrolaminar block will be performed under ultrasound guidance, as a single injection.
Study: NCT00779675

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
Study: NCT00649116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate Tablets 100 mg
Description: 100mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopressor® Tablets 100 mg
Description: 100mg, single dose fed
Study: NCT00917332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation (breathing and muscles) and guided imagery (safe place)
Description: intervention group: daily practice of relaxation and guided imagery CD, for a rew weeks, until childbirth.
Study: NCT02224872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant
Description: Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/M2 IV on days -6 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV on days -6, -5, 3, 4

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI
Description: 200 cGy on day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 40 mg/kg IV on days 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid mofetil
Description: 15 mg/kg PO/IV TID beginning on day 5 through day 35
Study: NCT04608266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesylate
Description: Camostat mesylate, oral administration 600mg/day (2 x 100mg tablets every 8 hours) for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, oral administration 2 tablets every 8 hours for 14 days
Study: NCT04237077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone coaching program
Description: telephone coaching program : 7 phone calls by nurse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no telephone coaching program
Description: no telephone coaching program : 7 phone calls by nurse
Study: NCT00599937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: early introduction of ATRA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA and or Chemo as maintenance
Description: patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA and or Chemo as maintenance
Description: patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA and or Chemo as maintenance
Description: patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
Study: NCT02407106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Streptococcus Salivarius BLIS K12
Description: Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
Study: NCT02607488

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1%
Description: Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1.5%
Description: Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2%
Description: Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]
Study: NCT03906669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: PO daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole and Prometrium
Description: PO daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen and Prometrium
Description: PO daily for 14 days
Study: NCT04125108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Pulmonary rehabilitation programs were designed to include both 30 minutes resistance and 30 minutes aerobic exercises. Eight basic resistnace exercises were used incorporating, bench press, leg press, leg curl, leg extension, toe raises, biceps curl, triceps curl, shoulder press. Additionally each exercise training session also included aerobic conditioning exercises ona treadmill or cycle ergometer. Aerobic exercise training was carried out 5 days per week, with each session lasting 30 minutes. All exercise sessions were preceded by a 5-minutes warm up period on a treadmill set.
Study: NCT03057691

Intervention type: OTHER
Intervention: antidepressive and anti-anxiety therapy
Description: These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.

Intervention type: OTHER
Intervention: antidepressive and anti-anxiety therapy
Description: These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.

Intervention type: OTHER
Intervention: antidepressive and anti-anxiety therapy
Description: These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
Study: NCT01633944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Buccal Film twice daily
Study: NCT03142503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet + supplementation
Description: Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet + placebo
Description: Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplementation of 1g soybean oil, 3 times a day.
Study: NCT01872572

Intervention type: DRUG
Group type: OTHER
Intervention: Subcutaneous RB006 0.5 mg/kg
Description: Subcutaneous RB006 0.5 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Subcutaneous RB006 0.5 mg/kg
Description: Subcutaneous RB006 0.5 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Subcutaneous RB006 1.0 mg/kg
Description: Subcutaneous RB006 1.0 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Subcutaneous RB006 3.0 mg/kg
Description: Subcutaneous RB006 3.0 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Subcutaneous RB006 2.0 mg
Description: * Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~* Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT01441193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 Tat/delta-V2 Env combined vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV-1 delta-V2 Env vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV-1 Tat vaccine 7.5 microg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV-1 Tat vaccine 30 microg
Study: NCT02694341

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal traction stitch
Description: Abdominal traction stitch to prevent prolapse of the Bakri balloon. A suture is tied through the uterine end shaft hole of the Bakri balloon. The other end of the suture is placed through the uterine wall. The balloon is positioned in the lower segment.The abdominal traction stitch is held by forceps and fixed, with cephalad traction applied continuously to the balloon, preventing balloon prolapse.The abdominal traction stitch is fixed by an umbilical cord clamp on the abdominal wall, preventing the suture from receding into the abdominal cavity, and, thus, maintaining the correct position of the balloon and preventing prolapse. Removal of the balloon is easy, with no resistance; the suture does not hinder balloon removal. At the time of balloon removal, the suture that was placed through the abdominal wall will traverse the intra-abdominal and intrauterine cavities, and should be kept clean.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bakri Balloon
Description: uterine compression balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bakri Balloon
Description: uterine compression balloon
Study: NCT02093637

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Placebo Comparator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture
Description: Experimental
Study: NCT03912233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ
Description: TEZ tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ
Description: TEZ tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ
Description: TEZ tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ
Description: TEZ tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Fixed-dose combination tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
Study: NCT00625599

Intervention type: OTHER
Intervention: Osteoporosis Prevention Information
Description: Primary investigator designed osteoporosis prevention information.

Intervention type: OTHER
Intervention: Osteoporosis Prevention Information
Description: Primary investigator designed osteoporosis prevention information.
Study: NCT03612622

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: Intermittent Theta-Burst Transcranial Magnetic Stimulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: Intermittent Theta-Burst Transcranial Magnetic Stimulation